AAI and CML merged in late 2013 to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.
Alcami recently invested in additional capabilities and capacity for oral solid dose manufacturing and parenteral fill-finish, including additional sterile lines and lyophilization. Additionally, Alcami will be relocating its current St. Louis Analytical Testing Services to a new facility at the Cortex Innovation Center in St. Louis, MO, which provides analytical testing for new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals.
Stephan Kutzer, chief executive officer, said, "With nearly 1000 employees at seven sites in the U.S. and Europe, these upgrades across our facilities in Wilmington, Charleston, Durham, Germantown, Edison, St. Louis, and Weert, the Netherlands, combined with enhancements in our quality, execution and customer focus, support the overall progress of our growth strategy as a contract services provider with a renewed commitment to meeting customer needs like never before. With increases in our capabilities and capacities across all our businesses, our ability to serve the market is stronger than ever."